Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

Japanese Journal of Clinical Oncology

Year: 2010  |  Volume: 40  |  Issue: 4  |  Page No.: 286 - 293

Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin

Y. Y Shao, K. T Kuo, F. C Hu, Y. S Lu, C. S Huang, J. Y Liau, W. C Lee, C Hsu, W. H Kuo, K. J Chang, C. H Lin and A. L. Cheng

Abstract

Objective

We studied tau and excision repair cross-complementing 1 expression to evaluate their predictive values in advanced breast carcinoma patients.

Methods

Patients treated with paclitaxel and cisplatin as the first-line chemotherapy for locally advanced or metastatic breast cancer were enrolled. The expression levels of tau and excision repair cross-complementing 1 were assessed by immunohistochemistry and examined for their associations with treatment response and survival.

Results

Fifty-four patients were included in this study. Despite the strong association between tau expression and lower histological grade and estrogen receptor expression, tau expression remained an independent predictor for a lower response rate in multivariate analysis (odd ratio = 0.24, P = 0.02). However, tau expression was a predictor for longer overall survival in both univariate analysis (median, 57.5 vs. 30.4 months, P = 0.02) and multivariate analysis (hazard ratio = 0.36, P = 0.008). Excision repair cross-complementing 1 was not associated with treatment response or overall survival.

Conclusions

Tau expression but not excision repair cross-complementing 1 in advanced breast cancer predicts poor response to combination chemotherapy of paclitaxel and cisplatin. However, tau expression is significantly associated with longer overall survival.

View Fulltext